医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

STENTYS Expands Marketing of its Stents in Asia

2014年01月09日 AM02:10
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J. & PARIS

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced the signing of the first distribution partnerships for its stents in Asia.

After establishing marketing in Europe and the Middle East, STENTYS continues its international development in partnership with national distributors specialized in cardiovascular products in Singapore, Hong Kong and Malaysia. This expansion is part of the Company’s strategy to promote its stent in countries that represent significant potential for the Self-Apposing® Stent and recognize the CE Mark.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, commented: “STENTYS’ sales expansion through national distributors in the Middle East was a substantial success in 2013, and we plan to replicate this model across Asia. The excellent feedback we have received from opinion leaders in this new region makes us confident that our stent will be rapidly adopted in Southeast Asia.

About the STENTYS Self-Apposing® Stent
The STENTYS Self-Apposing® Stent addresses the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients or patients with atypical artery anatomy. Its flexible, self expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel, in particular after an AMI as the vessel dilates and the clot dissolves. It reduces the risk of malapposition and complications associated with conventional stents in this setting. The STENTYS Self-Apposing Stent has been marketed in Europe since receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent is expected to receive CE Mark in H2 2014.

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents.
More information is available at www.stentys.com.

This press release contains forward looking statements about the Company’s business. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company’s BMS, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2011 Registration Document (document de référence) filed with the Autorité des Marchés Financiers in France on August 27, 2013 under number R.13-040 as such section may be updated from time to time.

STENTYS is listed on Comp. B of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT

CONTACT

STENTYS
Stanislas Piot, +33 (0)1 44 53 99 42
CFO
stan.p@stentys.com
or
NewCap.
Dusan
Oresansky / Pierre Laurent, +33 (0)1 44 71 94 93
Financial
Communication / Investor Relations
stentys@newcap.fr
or
US:
MacDougall Biomedical Communications

Charles Liles, 781 235 3060
Christine
Labaree or Hunter Marshall, 650 339 7533
stentys@macbiocom.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作